九洲药业(603456.SH)：公司收到化学原料药上市申请批准通知书

Core Viewpoint - Jiuzhou Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Tofisopam Tosylate, an oral anticoagulant drug aimed at preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as treating or preventing deep vein thrombosis and pulmonary embolism [1] Company Summary - The company submitted the marketing application for Tofisopam Tosylate to the National Medical Products Administration in July 2024 and has recently obtained the approval notification [1] - Cumulative research and development investment in Tofisopam Tosylate has reached approximately RMB 6.69 million [1] Industry Summary - The main manufacturers of Tofisopam Tosylate in China include Xiansheng Pharmaceutical Co., Ltd. and Shandong New Era Pharmaceutical Co., Ltd. [1] - Sales of Tofisopam Tosylate tablets in domestic sample hospitals and urban pharmacies amounted to approximately RMB 361 million in 2023 [1]